washington semaglutide & tirzepatide Maintenance therapy on or Semaglutide vs Tirzepatide: Complete Comparison
Description
Matching was separately performed for the GLP-1 RA, DM control, and non-DM control groups, targeting individuals from the GLP-1 RA group included in both matches
Global incidence and prevalence of nonalcoholic fatty liver disease
Most patients begin experiencing appetite suppression within 12 weeks, though meaningful weight loss (510% body weight) typically appears by 812 weeks of consistent treatment
Many didn't even know what dose they were on
Pharmaceutics , 17 (8), 1036
